Identification of eleven different mutations including six novel, in the arylsulfatase B gene in Iranian patients with mucopolysaccharidosis type VI
- 13 April 2019
- journal article
- research article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 46 (3) , 3417-3426
Abstract
Mucopolysaccharidosis VI is a rare autosomal recessive disorder caused by the deficiency of enzyme Arylsulfatase B. The enzyme deficiency leads to the accumulation of dermatan sulfate in connective tissue which causes manifestations related to MPS VI. Up to now, three different disease causing variants are reported in Iranian patients. In this study, we scanned ARSB gene of 13 Iranian patients from 12 families in whom all parents were consanguineous and from the same ethnicity except one family that were not consanguineous but co-ethnic. We found six not previously reported disease causing variants. We extracted DNA from peripheral blood samples of patients that were previously confirmed as MPS VI by clinical, biochemical and enzymatic assays including berry-spot test and fluorimetry, followed by PCR and direct sequencing. Computational approaches were used to analyze novel variants in terms of their impact on the protein structure. 11 disease causing variants and 15 polymorphisms were found. Six disease causing variants were novel and five were previously reported of which three were in Iranian population. Four of patients, who were unrelated, two by two had the same disease causing variant and polymorphisms, which indicates a possible founder effect. Our study also implicates genotype–phenotype correlation. Computational structural modeling indicated these disease causing variants might affect structural stability and function of the protein. Data of this study confirms the existence of mutational heterogeneity in the ARSB between Iranian patients. Disease causing variants with high frequency can be used in the prenatal diagnosis and genetic counseling. Also, the existence of the same variants and polymorphisms in some of the unrelated patients indicates a possible founder effect.Keywords
Funding Information
- Iran University of Medical Sciences (96-03-30-30735)
This publication has 35 references indexed in Scilit:
- Overview of the mucopolysaccharidosesRheumatology, 2011
- Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP)Journal of Inherited Metabolic Disease, 2011
- Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfacesBMC Bioinformatics, 2010
- Mucopolysaccharidosis VIOrphanet Journal of Rare Diseases, 2010
- Mutational analysis of 105 mucopolysaccharidosis type VI patientsHuman Mutation, 2007
- Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)American Journal of Medical Genetics Part A, 2005
- Structure validation by Cα geometry: ϕ,ψ and Cβ deviationProteins: Structure, Function, and Bioinformatics, 2003
- Maroteaux–Lamy syndrome: five novel mutations and their structural localizationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1999
- Acute infantile cardiomyopathy as a presenting feature of mucopolysaccharidosis VIThe Journal of Pediatrics, 1992
- Endocardial fibroelastosis in mucopolysaccharidosis type VIClinical Cardiology, 1987